Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$734 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $72 |
| Gross Profit | $0 | $0 | $0 | -$662 |
| % Margin | – | – | – | 90.2% |
| R&D Expenses | $11,915 | $12,613 | $13,012 | $20,731 |
| G&A Expenses | $3,586 | $3,711 | $3,988 | -$3,565 |
| SG&A Expenses | $3,586 | $3,711 | $3,988 | $8,269 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1,062 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,501 | $16,324 | $17,000 | $29,000 |
| Operating Income | -$15,501 | -$16,324 | -$17,000 | -$12,390 |
| % Margin | – | – | – | 1,688% |
| Other Income/Exp. Net | $0 | $0 | $0 | $49,731 |
| Pre-Tax Income | $0 | $0 | $0 | $37,341 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $37,341 |
| % Margin | – | – | – | -5,087.3% |
| EPS | -1.09 | -1.14 | 0 | 1.08 |
| % Growth | 4.4% | – | -100% | – |
| EPS Diluted | -1.09 | -1.14 | 0 | 1.08 |
| Weighted Avg Shares Out | 135,309 | 135,091 | 34,471 | 34,471 |
| Weighted Avg Shares Out Dil | 135,309 | 135,091 | 34,471 | 34,471 |
| Supplemental Information | – | – | – | – |
| Interest Income | $804 | $934 | $1,075 | $2,013 |
| Interest Expense | $2 | $0 | $0 | -$300 |
| Depreciation & Amortization | $204 | $0 | $0 | -$72 |
| EBITDA | $204 | -$16,324 | -$17,000 | $35,937 |
| % Margin | – | – | – | -4,896.1% |